Studies of the effect of auranofin, a new antiarthritic agent, on platelet aggregation.
Auranofin (AF), at a concentration of 10 micrograms/ml, was found to be a potent inhibitor of ADP-, epinephrine-, or collagen-induced platelet aggregation utilizing platelet-rich plasma obtained from human blood. In contrast, aurothioglucose was less effective than AF in inhibiting epinephrine- or collagen- induced platelet aggregation. The inhibitory effect of AF was more evident on the second phase of aggregation. The inhibitory effect of AF was more evident on the second phase of aggregation and was a function of drug preincubation time. Compared to platelet-rich plasma, washed platelets were superior for detecting the inhibitory action of AF (greater than or equal to 0.1 microgram/ml) on ADP-induced platelet aggregation. This potent inhibitory action of AF on ADP-induced platelet aggregation was antagonized by dithioerythriol, a potent reducing agent. These results suggest that AF can inhibit both platelet release and aggregation mechanisms which may be relevant to its antiarthritic activity. Further studies are required to elucidate the cellular mechanism by which AF inhibits platelet aggregation.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000494:pharmacology; D001792:Blood Platelets; D004226:Dithioerythritol / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D006046:Gold / Q000031:analogs & derivatives*; D006801:Humans; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D006051:Aurothioglucose; D001310:Auranofin; D000244:Adenosine Diphosphate; D004226:Dithioerythritol; D006046:Gold; D004837:Epinephrine